Close

Pfenex IPO Info

Company Name: Pfenex
Stock Symbol: PFNX
Exchange: NYSE
Status: Priced
IPO Date: 7/24/2014
IPO Price: 6.00 (19.67%)
Underwriters
William Blair & Company, L.L.C. and JMP Securities LLC

Amount of Offering: N/A
Number of Shares Offered: 8.333 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology™ platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.